Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.

MLA

Kato, Junko, et al. “Combination Therapy with Zoledronic Acid and Cetuximab Effectively Suppresses Growth of Colorectal Cancer Cells Regardless of KRAS Status.” International Journal of Cancer, vol. 138, no. 6, Mar. 2016, pp. 1516–27. EBSCOhost, https://doi.org/10.1002/ijc.29881.

APA

Kato, J., Futamura, M., Kanematsu, M., Gaowa, S., Mori, R., Tanahashi, T., Matsuhashi, N., & Yoshida, K. (2016). Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. International Journal of Cancer, 138(6), 1516–1527. https://doi.org/10.1002/ijc.29881

Chicago

Kato, Junko, Manabu Futamura, Masako Kanematsu, Siqin Gaowa, Ryutaro Mori, Toshiyuki Tanahashi, Nobuhisa Matsuhashi, and Kazuhiro Yoshida. 2016. “Combination Therapy with Zoledronic Acid and Cetuximab Effectively Suppresses Growth of Colorectal Cancer Cells Regardless of KRAS Status.” International Journal of Cancer 138 (6): 1516–27. doi:10.1002/ijc.29881.